Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — B of A Securities 2022 Healthcare Conference
8 slides from Century Therapeutics's conference presentation, May 10, 2022
Slide 1: B of A Securities 2022 Healthcare Conference
1 May 10, 2022 B of A SECURITIES 2022 HEALTHCARE CONFERENCE
Slide 2: Forward-Looking Statements
2 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of , The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical f
Slide 3: Future Vision
3 3 Future Vision Century is developing transformative allogeneic cell therapies Establish franchises in B cell malignancies, GBM, solid tumor indications World - class cell engineering and manufacturing capabilities Develop best - in - class iPSC - derived iNK and iT cell platforms Financial streng
Slide 4: ELiPSE-1 Phase 1 Study Goals and CNTY-101 Profile
4 4 ELIPSE - 1: PHASE 1 STUDY GOALS • Dose escalation with multiple doses and single lymphodepletion conditioning regimen • IND submission on track for mid - 2022 to advance CNTY - 101 into Phase 1 clinical trial CNTY - 101: NEXT GENERATION CD19 TARGETED PRODUCT CNTY - 101 HLA - I Knockout IL - 15 H
Slide 5: Common Progenitor Enables Efficient Pipeline Expansion
5 5 COMMON PROGENITOR ENABLES EFFICIENT PIPELINE EXPANSION iNK 1.0 iNK 3.0 Common Progenitor Candidate 1 Candidate 2 Candidate 3 iNK 3.0 common progenitor platform incorporates multiple features: • Additional Allo - Evasion edits • Additional innate killing potential • Additional anti - cancer targe
Slide 6: Product Candidate Pipeline
6 6 Product iPSC Platform Targets Indications Expected IND Submission Discovery Preclinical Clinical Collaborator CNTY - 101 iNK CD19 B - Cell Malignancies Mid 2022 CNTY - 103 iNK CD133 + EGFR Glioblastoma 2023 CNTY - 102 iT CD19 + CD79b B - Cell Malignancies 2024 CNTY - 104 iNK/ iT Multi - specific
Slide 7: Century Therapeutics' Unique Investment Opportunity
7 7 CENTURY THERAPEUTICS’ UNIQUE INVESTMENT OPPORTUNITY We are developing a portfolio of potentially best - in - class, differentiated allogeneic cell therapies that deliver durable responses We are leveraging our iNK and δγ iT cell platforms to tackle tumors with unmet medical need Our comprehensiv
Slide 8: Century Therapeutics
CENTURY THERAPEUTICS
Century Therapeutics — B of A Securities 2022 Healthcare Conference on 6ix